



The Interstitial Lung Diseases: From Pathogenesis to Therapy

Guest Editors:

Dr. Marina Ruxandra Otelea

Clinical Department 5, Carol Davila University of Medicine and Pharmacy, 050474 Bucharest, Romania

Dr. Oana Cristina Arghir

Pulmonology Department, Faculty of Medicine, Ovidius University of Constanta, 900527 Constanța, Romania

Deadline for manuscript submissions:

closed (30 April 2023)

Message from the Guest Editors

Dear Colleagues,

The classification of interstitial lung diseases (ILDs) continues to evolve, but even with modern diagnosis techniques, some ILDs remain unclassifiable. On the other hand, many diseases which are not classified as ILDs (such as tuberculosis or COPD) have an interstitial component, which should receive further study so that appropriate treatment can be developed.

Recent advances in diagnosis and therapy have led to improved treatment, but only a comprehensive characterisation of the interstitial pathology, including etiological factors, biomarkers, phenotypes, and treatable traits, will allow for the introduction of precision medicine interventions.

We invite colleagues with an interest in this field of research to submit original research or review articles that contribute to the current body of knowledge on interstitial pathology, focusing in a broader sense on the pathogenic mechanisms that alter the interstitium. In this way, we hope to enhance the current understanding of the environmental and immunological factors of disease development and progression and the therapeutical approach.

Dr. Marina Ruxandra Otelea

Dr. Oana Cristina Arghir

Guest Editors





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Felipe Fregni

1. Neuromodulation Center and
Center for Clinical Research
Learning, Spaulding
Rehabilitation Hospital and
Massachusetts General Hospital,
Harvard Medical School, Boston,
MA 02114, USA
2. Department of Epidemiology,
Harvard T.H. Chan School of
Public Health, Boston, MA 02115,
USA

Message from the Editor-in-Chief

Biomedicines (ISSN 2227-9059) is an open access journal devoted to all aspects of research on human health and disease, the discovery and characterization of new therapeutic targets, therapeutic strategies, and research of naturally driven biomedicines, pharmaceuticals, and biopharmaceutical products. Topics include pathogenesis mechanisms of diseases, translational medical research, biomaterial in biomedical research, natural bioactive molecules, biologics, vaccines, gene therapies, cell-based therapies, targeted specific antibodies, recombinant therapeutic proteins, nanobiotechnology driven products, targeted therapy, bioimaging, biosensors, biomarkers, and biosimilars. The journal is open for publication of studies conducted at the basic science and preclinical research levels. We invite you to consider submitting your work to *Biomedicines*, be it original research, review articles, or developing Special Issues of current key topics.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within *Scopus*, *SCIE (Web of Science)*, *PubMed*, *PMC*, *CAPlus / SciFinder*, and other databases.

Journal Rank: JCR - Q1 (Pharmacology and Pharmacy) / CiteScore - Q2 (*Medicine (miscellaneous)*)

Contact Us

Biomedicines Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/biomedicines
biomedicines@mdpi.com
X@Biomed_MDPI